Dec 07, 2016 14:00 pm UTC| Business
JUST Capitalpartners with GoodData® to create the foundation and single source of truth to identify JUST companies. With multiple disparate data sources and the need to manage complex data transformation, JUST Capital...
Five Star Bank Names Craig Burton Senior Vice President, Commercial Real Estate Executive
Dec 07, 2016 14:00 pm UTC| Business
WARSAW, N.Y., Dec. 07, 2016 -- Five Star Bank (“Five Star” or the “Bank”), subsidiary of Financial Institutions, Inc. (NASDAQ:FISI), today announced the hiring of Craig Burton as Senior Vice President, Commercial Real...
Xively Sets the Bar for IoT Scale & Performance; Leading Analyst Firm Finds
Dec 07, 2016 14:00 pm UTC| Business
BOSTON, Dec. 07, 2016 -- Today Xively by LogMeIn, Inc. (NASDAQ:LOGM) and Enterprise Strategy Group (ESG), a leading IT analyst, research, validation, and strategy firm released the results of an IoT scalability...
Integra LifeSciences Announces Expansion and Extension of Credit Facility to $1.5 Billion
Dec 07, 2016 13:51 pm UTC| Business
PLAINSBORO, N.J., Dec. 07, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has increased its credit facility with its bank group led by Bank of America, N.A. The expanded and...
NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares
Dec 07, 2016 13:50 pm UTC| Business
REHOVOT, Israel, Dec. 07, 2016 -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of a follow-on offering of...
Dec 07, 2016 13:50 pm UTC| Business
Hancock, MD, Dec. 07, 2016 -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to...
Dec 07, 2016 13:50 pm UTC| Business
Initial goal to determine treatment efficacy of iTeos' immuno-oncology drug candidatesOption for iTeos to license Cristal's proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic...